{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:18:52Z","timestamp":1790194732506,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Ubrogepant (Ubrelvy), a CGRP receptor antagonist, is approved for acute treatment of migraine with or without aura in adults. Because ubrogepant treats a neurological condition, it is of interest to know central nervous system exposure. Ubrogepant concentrations in plasma and cerebrospinal fluid (CSF) were measured in participants with a history of migraine. This analysis included a subset of participants with a \u2265\u20091\u2009year history of migraine who were enrolled in a Phase 1b multi\u2010center, open\u2010label trial and who underwent a single CSF collection via lumbar puncture. All participants received a single oral dose of 100\u2009mg ubrogepant. Plasma and CSF ubrogepant concentrations were measured using LC\u2013MS\/MS at pre\u2010defined post\u2010dose timepoints (plasma: 0\u201324\u2009h; CSF: 2 or 4\u2009h). Ubrogepant CSF\/plasma concentration ratios at 2 and 4\u2009h were determined. Ubrogepant safety and tolerability were evaluated through reporting of treatment\u2010emergent adverse events (TEAEs; \u2264\u200930\u2010days after dosing), physical examination, ECG, laboratory testing, and vital sign monitoring. A total of 8 participants were included. Mean (\u00b1SD) age was 34.5\u2009\u00b1\u20099.58\u2009years and 4 participants (50%) were male. At 2\u2009h, mean (\u00b1SD) CSF and plasma ubrogepant concentrations were 1.1\u2009\u00b1\u20090.8 and 354\u2009\u00b1\u2009163\u2009ng\/mL, respectively (CSF\/plasma ratio: 0.36%\u2009\u00b1\u20090.29%); at 4\u2009h, 2.3\u2009\u00b1\u20091.9 and 218\u2009\u00b1\u200984\u2009ng\/mL, respectively (CSF\/plasma ratio: 0.94%\u2009\u00b1\u20090.64%). No serious TEAEs, deaths, or significant changes in laboratory values, vital signs, or ECGs occurred. Because ubrogepant half maximal effective concentration (EC\n                    <jats:sub>50<\/jats:sub>\n                    ) has been estimated at ~1.4\u2009ng\/mL, ubrogepant could act both centrally and peripherally to relieve migraine symptoms.\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    , NCT04179474 (registration date: 27 November 2019).\n                  <\/jats:p>","DOI":"10.1111\/cts.70560","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:12:31Z","timestamp":1776773551000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open\u2010Label Trial"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8267-9210","authenticated-orcid":false,"given":"Ramesh R.","family":"Boinpally","sequence":"first","affiliation":[{"name":"Clinical Pharmacology, AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-8878","authenticated-orcid":false,"given":"Joel M.","family":"Trugman","sequence":"additional","affiliation":[{"name":"Clinical Development, AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-024-00690-7"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6725-x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.8.813"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00530-0"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231159366"},{"key":"e_1_2_9_8_1","volume-title":"UBRELVY (Ubrogepant) [Package Insert]","year":"2025"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14095"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.261065"},{"key":"e_1_2_9_13_1","unstructured":"European Medicines Agency (EMA) Inc \u201cAssessment Report: Aquipta (Atogepant) (EMA\/CHMP\/326142\/2023) \u201d(2023) accessed 20 October 2025 https:\/\/www.ema.europa.eu\/en\/documents\/assessment\u2010report\/aquipta\u2010epar\u2010public\u2010assessment\u2010report_en.pdf."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.206458"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413476372"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01894-0"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418786261"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2008.01298.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph3061966"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-9905-5"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph3051335"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.133868"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70560","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70560","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:24:57Z","timestamp":1777955097000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/cts.70560"],"URL":"https:\/\/doi.org\/10.1111\/cts.70560","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2026-01-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70560"}}